Work

SAT-116 Vitamin D supplementation in the Treatment of Polycystic Ovary Syndrome (PCOS)

Year: 2025

Type: conference-abstract

Abstract: Disclosure: A.D. Felomeno: None. M.S. Duarte: None. I.C. Maluly: None. F.B. Morais: None. I.P. Rufino: None. B.G. Silva: None. G.D. Grilo: None. L.M. Canale: None. L.M. Teixeira: None. C.G. Moreira: None. N. Patricio Lopes: None. N.K. Balarezo: None. INTRODUCTIONPolycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by chronic anovulation, hyperandrogenism, and polycystic ovaries. It is often linked to metabolic complications such as insulin resistance, obesity, and chronic inflammation. Vitamin D has been studied as a potential modulator beyond bone metabolism, enhancing insulin sensitivity by regulating pancreatic beta-cell function and reducing inflammation—key aspects in PCOS management. METHODOLOGY This systematic review was conducted in January 2025 using the PubMed database with the terms “Polycystic Ovary Syndrome” and “Vitamin D,” combined with AND. Randomized clinical trials published in English within the last five years were included, while unrelated studies were excluded. After screening, three studies were selected. RESULTS Javed et al. (2019) found that after three months of supplementation with 3,200 IU/day, ALT levels significantly decreased (p = 0.042), while the placebo group showed an increase (p = 0.039). There was also a drop in ELF score (p = 0.022) and hyaluronic acid levels (p = 0.019), though without statistical significance between groups. No major metabolic changes were noted. Wen et al. (2024) analyzed supplementation with 2,000 IU/day for 12 weeks and found a significant rise in serum vitamin D levels (p = 0.008). They also observed reductions in BMI (p = 0.041) and waist-to-hip ratio (p = 0.043), while the placebo group showed no changes. Insulin and HOMA-IR levels were lower in the supplemented group (p < 0.05), as well as TG, TC, and LDL-C (p < 0.05). Trummer et al. (2019) showed that 20,000 IU/week of cholecalciferol increased serum 25(OH)D (p < 0.001), reduced insulin resistance (HOMA-IR, p = 0.04), and lowered total testosterone (p = 0.03). Lipid profile improved, with HDL increasing (p = 0.04) and LDL decreasing (p = 0.03). AMH levels remained unchanged (p = 0.08), but findings reinforce vitamin D’s therapeutic role in PCOS. The studies suggest vitamin D supplementation may improve metabolic and hepatic parameters, including ALT, BMI, HOMA-IR, and lipid profile. However, heterogeneity in findings underscores the need for further research to standardize therapeutic protocols. CONCLUSION The findings suggest vitamin D supplementation may benefit women with PCOS, particularly by improving insulin resistance, liver function, and lipid profile. While results highlight its potential in metabolic management, more studies are needed to establish definitive guidelines. Presentation: Saturday, July 12, 2025

Source: Journal of the Endocrine Society

DOI: 10.1210/jendso/bvaf149.1967